Dr Charles Harrington
BSc (Hons) (Glasgow, 1977); PhD (Glasgow, 1980)
Senior Research Fellow
Charlie Harrington graduated in Microbiology from Glasgow University where he developed an interest in chemical microbiology and the study of microbial cell walls. He completed his PhD working with Dr Julia Douglas on cell wall synthesis in yeast and followed with a one-year NIH-funded Fellowship with Dr Wilf Arnold in Kansas City, Missouri studying enzymes within the yeast cell envelope. After this, Charlie joined Professor Sir James Baddiley in the Department of Biochemistry at the University of Cambridge as a Research Fellow, where he spent four years investigating the synthesis of bacterial cell wall polymers. Dr Harrington then spent over two years at Murex Medical Research Ltd., Cambridge, developing diagnostic tests for microbial diseases, including methicillin-resistant Staphylococcus aureus and sexually transmitted diseases. This combined monoclonal antibody technology with his knowledge of the microbial cell surface.
In 1988, he joined Claude Wischik working at the Medical Research Council’s Laboratory of Molecular Biology. Working in the Cambridge Brain Bank Laboratory over a period of 10 years. During this time, Wischik, Harrington and colleagues developed an assay for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease. Charlie moved with Professor Wischik, in 1998, to the University of Aberdeen, where he was appointed as a Senior Research Fellow.
The Alzheimer's research was translated to the clinic, through a spin-out company, TauRx Therapeutics, who are conducting phase 3 trials of hydromethylthionine. Dr Harrington is Chief Scientific Officer for TauRx Therapeutics Ltd responsible for the non-clinical activities of the company.
- BSc (Hons) Microbiology1977 - University of Glasgow
- PhD Microbiology1980 - University of Glasgow
Proteomic analysis of hydromethylthionine in the line 66 model of frontotemporal dementia demonstrates actions on tau-dependent and tau-independent networksCells, vol. 10, no. 8, 2162Contributions to Journals: Articles
Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementiaBrain CommunicationsContributions to Journals: Articles
Tau Protein Phosphorylated at Threonine-231 Is Expressed Abundantly in the Cerebellum in Prion EncephalopathiesJournal of Alzheimer's Disease, vol. 81, no. 2, pp. 769-785Contributions to Journals: Articles
Elucidating the neuropathologic mechanisms of SARS-CoV-2 infectionFrontiers in Neurology, vol. 12, 660087Contributions to Journals: Articles
Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer’s Disease BrainsInternational Journal of Molecular Sciences, vol. 22, no. 7, 3654Contributions to Journals: Articles
Dr Harrington has research interests in the neurodegenerative diseases and, in particular, Alzheimer’s disease. His main focus has been on the biology of tau protein in aging and in Alzheimer’s disease. Dr Harrington’s research is aimed at diseases that are characterised by protein aggregation and methods by which these processes might be prevented.
Page 5 of 8 Results 41 to 50 of 78
Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's DiseaseJournal of Pharmacology and Experimental Therapeutics, vol. 352, no. 1, pp. 110-118Contributions to Journals: Articles
Tau-aggregation inhibitor therapy for Alzheimer's diseaseBiochemical Pharmacology, vol. 88, no. 4, pp. 529-539Contributions to Journals: Articles
TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, pp. S26Contributions to Journals: Abstracts
Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: neuronal localization and possible functionNeurobiology of Aging, vol. 34, no. 5, pp. 1380-1388Contributions to Journals: Articles
New phenothiazine diaminium compounds are tau protein aggregation inhibitors, useful to treat e.g. Alzheimer's disease, Pick's disease, progressive supranuclear palsy, frontotemporal dementia and frontotemporal lobar degeneration syndromesPatents: Patents
The molecular pathology of Alzheimer's diseaseNeuroimaging Clinics of North America, vol. 22, no. 1, pp. 11-22Contributions to Journals: Literature Reviews
3,7-diamino-10H-phenothiazine salts and their use: WO2007110627Patents: Patents
Stripline resonator and preamplifier for preclinical magnetic resonance imaging at 4.7 TMagnetic Resonance Materials in Physics, Biology and Medicine, vol. 24, no. 6, pp. 331-337Contributions to Journals: Articles
3,6-Disubstituted xanthylium saltsPatents: Patents
Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC): methods of treatment of a tauopathy condition comprising the use of thioninium compoundsPatents: Patents